Biotechnology company Dantari raised USD 47 million in a Series A funding round led by Westlake Village BioPartners, along with participation from other venture capital firms and individual investors. 

The funds will be used to further the development of the company’s differentiated antibody-drug conjugate (ADC) and chemotherapeutic platforms. 

Post-funding the company also announced its appointment of Richard Markus as president and CEO, and its board of directors would be chaired by Sean Harper a co-founding managing director at Westlake.

California-based Dantari is a biotechnology company that focuses on developing treatments for cancers along with other diseases. The company’s chemotherapeutic candidate, DAN-22, is being developed using ADC and Targeted High-capacity Drug Conjugate technology originating from Caltech and is in Phase 1/2 trial for HER2-negative breast cancer. The company also has another candidate, DAN311, slated for human testing in 2023. Dantari’s candidates are being developed to use a variety of delivery systems, with its trials being currently carried out.